Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633511 | 0.79 | DRD3 (0.36) | — | |
| SCHEMBL4125324 | 0.78 | GSK3B (0.40) | SLC6A3KCNH2TAAR1 | |
| SCHEMBL12610342 | 0.77 | AKR1C3 (0.42) | SLC6A3KCNH2TAAR1 | |
| SCHEMBL12610345 | 0.77 | AKR1C3 (0.42) | SLC6A3KCNH2TAAR1 | |
| SCHEMBL295269 | 0.76 | CNR2 (0.46) | — | |
| SCHEMBL3120324 | 0.76 | NPC1 (0.36) | SLC6A3 | |
| SCHEMBL25178052 | 0.75 | CNR2 (0.56) | — | |
| SCHEMBL31116738 | 0.75 | CNR2 (0.56) | — | |
| SCHEMBL29108413 | 0.74 | CHRNB2 (0.47) | CHRNB2CHRNA3CHRNA7CHRNA4CHRNB4 | |
| SCHEMBL28935169 | 0.72 | MOK (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
| WO-2007089193-A1 | A PROCESS FOR PREPARING 2-HYDROXY-3- [5- (MORPHOLIN-4-YLMETHYL)PYRIDIN-2-YL] LH-INDOLE-5-CARBONITRILE AS A FREE BASE OR SALTS THEREOF | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | CHRNB2 4057/4885CHRNA3 4171/4885CHRNA7 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.